SCHEMBL23286263

SCHEMBL23286263

N#Cc1ccc(COc2cc(F)cc(Br)c2)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.41
DHFR P00374 1/20 0.41
DCPS Q96C86 1/20 0.41
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MAOB P27338 4/20 0.39
KCNH2 Q12809 1/20 0.38
GPR119 Q8TDV5 1/20 0.38
GSK3B P49841 1/20 0.36
BACE1 P56817 1/20 0.36
PTGER1 P34995 1/20 0.36
HPD P32754 1/20 0.35
NR3C1 P04150 1/20 0.34
PGR P06401 1/20 0.34
NR3C2 P08235 1/20 0.34
RORC P51449 1/20 0.34
PRMT5 O14744 1/20 0.34
EGFR P00533 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23286738 0.90 NPC1 (0.40) MAPK14DHFRDCPSNPC1RAB9A
SCHEMBL23286871 0.87 MAPK14 (0.40) MAPK14DHFRDCPSNPC1RAB9A
SCHEMBL29664227 0.84 MAOB (0.50) MAPK14NPC1RAB9AMAOBKCNH2
SCHEMBL23362070 0.84 MAOB (0.50) MAPK14NPC1RAB9AMAOBKCNH2
SCHEMBL19745238 0.80 MAOB (0.51) MAOBKCNH2GPR119PTGER1HPD
SCHEMBL30497257 0.80 PTGER1 (0.46) MAPK14DHFRDCPSMAOBGSK3B
SCHEMBL23286794 0.80 MAOB (0.40) MAPK14NPC1RAB9AMAOBKCNH2
SCHEMBL29194904 0.77 KCNH2 (0.39) MAPK14NPC1RAB9AMAOBKCNH2
SCHEMBL23287166 0.77 MAPK14 (0.44) MAPK14NPC1RAB9APTGER1PRMT5
SCHEMBL31425070 0.77 MAPK14 (0.44) MAPK14NPC1RAB9APTGER1PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119874674-A GLP-1R modulating compounds 吉利德科学公司 2025-04-25 CN disclosed
CN-114630823-B GLP-1R Modulating Compounds 吉利德科学公司 2025-01-28 CN disclosed
US-11702404-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2023-07-18 US disclosed
US-11702404-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2023-07-18 US disclosed
CN-114630823-A GLP-1R modulating compounds 吉利德科学公司 2022-06-14 CN disclosed
US-20210171499-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2021-06-10 US disclosed
WO-2021081207-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2021-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702404-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 MAPK14 2254/4885DHFR 4805/4885DCPS 3194/4885
US-20210171499-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 MAPK14 2254/4885DHFR 4805/4885DCPS 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.